Neos Therapeutics, Inc. (NEOS) CEO Jerry McLaughlin on Q3 2019 Results - Earnings Call Transcript

Neos Therapeutics, Inc. (NASDAQ:NEOS) Q3 2019 Earnings Conference Call November 8, 2019 8:30 AM ET

Company Participants

Jerry McLaughlin - Chief Executive Officer
Richard Eisenstadt - Chief Financial Officer

Conference Call Participants

Louise Chen - Cantor Fitzgerald
Ken Cacciatore - Cowen & Company
Jason Butler - JMP Securities
Rafay Sardar - BMO Capital Markets

Operator

Thank you for holding. Good morning, and welcome to the Neos Therapeutics' Third Quarter 2019 Financial Results Conference Call. Today's call is being recorded. At this time, all participants are in a listen-only mode. There will be a question-and-answer session to follow.

For introductory and opening remarks, I am turning the call over to Mr. Richard Eisenstadt, CFO of Neos Therapeutics. Please go ahead.

Richard Eisenstadt

Thank you. Good morning, everyone, and welcome to our third quarter 2019 financial results conference call. This morning, we issued our financial results and corporate highlights press release, which is available on our website at www.neostx.com. I am joined on today's call by Jerry McLaughlin, our CEO.

Before we begin, I'd like to read the following regarding forward-looking statements. During this call, we will make statements related to our business that may be considered forward-looking and are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 including statements concerning the commercialization of Adzenys XR-ODT, Cotempla XR-ODT and Adzenys ER oral suspension, the financial results of and outlook for our business including with respect to net revenue per pack, script volumes, market share, intended benefits of our commercial strategy, our expectations regarding the brand exclusivity for our ADHD products, our patient access programs Neos Rx Connect, the capabilities of our technology and our research and development activities including the timing and progress of our product candidates, future expansion of our product pipeline to business development activities and our current and future financial position.